Sugi Predict

Sugi Predict / Compounds / SCHEMBL13385342

SCHEMBL13385342

SCHEMBL13385342

Cc1cccc(N(C)C)c1C(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.41
▸ GAA P10253 4/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ ALDH1A1 P00352 4/20 0.37
▸ NSD2 O96028 1/20 0.37
▸ EGFR P00533 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ CA2 P00918 3/20 0.37
▸ CA1 P00915 2/20 0.37
▸ CA7 P43166 2/20 0.37
▸ CA9 Q16790 2/20 0.37
▸ TSHR P16473 3/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP2A6 P11509 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ MCL1 Q07820 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22429127 0.86 MAPT (0.48) MAPTGAAKDM4EALDH1A1NSD2
SCHEMBL7028664 0.78 GABRA1 (0.43) MAPTGAAKDM4EALDH1A1NSD2
SCHEMBL598366 0.78 CA1 (0.50) ALDH1A1LMNACA2CA1CA7
SCHEMBL24603705 0.77 MAPT (0.40) MAPTGAAKDM4EALDH1A1NSD2
SCHEMBL2273362 0.77 MAPT (0.40) MAPTGAAKDM4EALDH1A1NSD2
SCHEMBL13385304 0.76 ALDH1A1 (0.35) MAPTKDM4EALDH1A1LMNATDP1
SCHEMBL28373135 0.75 LMNA (0.34) MAPTGAAKDM4EALDH1A1LMNA
SCHEMBL20285959 0.72 P2RX7 (0.39) MAPTGAAKDM4EALDH1A1NSD2
SCHEMBL1911943 0.72 MAPT (0.48) MAPTGAAKDM4EALDH1A1NSD2
SCHEMBL30733276 0.72 MAPT (0.48) MAPTGAAKDM4EALDH1A1NSD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10889593-B2 Compounds targeting proteins, compositions, methods, and uses thereof BIOTHERYX, INC. (US) 2021-01-12 — — US disclosed
US-20190322683-A1 COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF BIOTHERYX, INC. 2019-10-24 — — US disclosed
US-10040804-B2 Compounds targeting proteins, compositions, methods, and uses thereof BIOTHERYX, INC. (US) 2018-08-07 — — US disclosed
US-10040804-B2 Compounds targeting proteins, compositions, methods, and uses thereof BIOTHERYX, INC. (US) 2018-08-07 — — US disclosed
US-20180170948-A1 COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF Bio TheryX, Inc. 2018-06-21 — — US disclosed
US-20180170948-A1 COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF Bio TheryX, Inc. 2018-06-21 — — US disclosed
US-20100102710-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-04-29 — — US disclosed
US-20090261714-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2009-10-22 — — US disclosed
US-20090252990-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2009-10-08 — — US disclosed
US-20090184629-A1 Novel red electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2009-07-23 — — US disclosed
US-20090153037-A1 Novel red electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2009-06-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090261714-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same AOX1, ODC1, LEF1 MAPT 2705/4885GAA 1944/4885KDM4E 2044/4885
US-20090252990-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same AOX1, LEF1, ODC1 MAPT 2613/4885GAA 2028/4885KDM4E 2236/4885
US-20180170948-A1 COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF CKS1B, IKZF3, EPAS1 MAPT 774/4885GAA 2868/4885KDM4E 4006/4885
US-20090153037-A1 Novel red electroluminescent compounds and organic electroluminescent device using the same NDUFS2, ALDH1A2, ODC1 MAPT 1708/4885GAA 1590/4885KDM4E 1792/4885
US-20090184629-A1 Novel red electroluminescent compounds and organic electroluminescent device using the same IK, TYR, EYA2 MAPT 1074/4885GAA 1961/4885KDM4E 1716/4885
US-20100102710-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ODC1, AOX1, OR10J3 MAPT 2098/4885GAA 1287/4885KDM4E 1974/4885
US-10889593-B2 Compounds targeting proteins, compositions, methods, and uses thereof CKS1B, IKZF3, EPAS1 MAPT 774/4885GAA 2868/4885KDM4E 4006/4885
US-10040804-B2 Compounds targeting proteins, compositions, methods, and uses thereof CKS1B, IKZF3, EPAS1 MAPT 774/4885GAA 2868/4885KDM4E 4006/4885
US-20190322683-A1 COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF CKS1B, IKZF3, EPAS1 MAPT 774/4885GAA 2868/4885KDM4E 4006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.